Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series
Rheumatology Advances in Practice · 12.04.2023 · 7 (2)
DOI: 10.1093/rap/rkad049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 09.06.2023. Verfasst von Debaditya Roy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, India. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Cutaneous polyarteritis nodosa (CPAN) is a distinct clinical entity represented by a chronic, relapsing, benign course, with rare systemic involvement. Treatment is with CSs, CYC or other conventional synthetic DMARDs (csDMARDs). In this case series, we aimed to share our varied clinical experience of successfully treating patients with CPAN, with tofacitinib in a refractory/relapsing course or as upfront monotherapy without CSs/csDMARDs.
Methods
We report this retrospective case series managed at our rheumatology centre in Bangalore from 2019 to 2022. Four patients identified as CPAN on biopsy were able to achieve disease-free remission with tofacitinib as part of their treatment, with no relapse on further follow-up. Our patients presented with subcutaneous nodules and cutaneous ulcers. After systemic evaluation, all the patients underwent skin biopsy, which showed fibrinoid necrosis in the vessel walls of the dermis, with a histopathological impression of CPAN. They were initially treated with a conventional approach of CSs with/without csDMARDs. On experiencing a refractory/relapsing course, tofacitinib was tried in all the patients as either CS sparing or upfront monotherapy without concomitant csDMARDs.
Results
Use of tofacitinib resulted in improvement of ulcers and paraesthesia and in gradual healing of skin lesions, albeit with scarring, with no further recurrence or relapse over a follow-up period of 6 months for all the patients. The therapeutic effect of tofacitinib was consistent when used either as CS sparing or as upfront monotherapy, thereby proving the drug to be a promising option that warrants larger trials in future to treat the subset of patients with established CPAN.
Conclusion
Tofacitinib could be used for disease-free remission as monotherapy for CPAN either upfront or as CS sparing, even without concomitant csDMARDs, in those patients who are dependent on CSs or multiple DMARDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, India.
- Department of Rheumatology, Divisha Arthritis and Medical Center, Bangalore, India.
- Chord Road Hospital, Bangalore, India.
- Divisha Arthritis and Medical Center, Bangalore, India.
ORCID-Profile: Debaditya Roy
Zitieren
APA
Roy, D., Sathyanarayana, V. A., Nagaraju, B., & Rao, V. K. R. (2023). Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series. Rheumatology Advances in Practice, 7(2). https://doi.org/10.1093/rap/rkad049
Vancouver
Roy D, Sathyanarayana VA, Nagaraju B, Rao VKR. Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series. Rheumatology Advances in Practice. 2023;7(2). doi:10.1093/rap/rkad049
BibTeX
@article{Roy2023,
author = {Roy, Debaditya and Sathyanarayana, Vanitha Agrahara and Nagaraju, Bhavya and Rao, Vijay K R},
title = {Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series},
journal = {Rheumatology Advances in Practice},
year = {2023},
volume = {7},
number = {2},
doi = {10.1093/rap/rkad049}
}
EUVIMED